| Identification | Back Directory | [Name]
Pamrevlumab | [CAS]
946415-13-0 | [Synonyms]
Pamrevlumab
Pamrevlumab (anti-CTGF)
Research Grade Pamrevlumab
Research Grade Pamrevlumab(DHD82301) |
| Hazard Information | Back Directory | [Uses]
FG-3019 (Pamrevlumab) is a recombinant human antibody that binds to connective tissue growth factor (CTGF). FG-3019 can be used for the research of idiopathic pulmonary fibrosis (IPF)[1][2]. | [in vivo]
FG-3019 (30 mg/kg; i.p. every 3 d for 9 d) in combination with Gemcitabine acutely decreases mouse pancreatic ductal adenocarcinoma (PDA) growth and induces neoplastic cell apoptosis in LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice[2]. | [References]
[1] Sgalla G, et, al. Pamrevlumab for the treatment of idiopathic pulmonary fibrosis. Expert Opin Investig Drugs. 2020 Aug;29(8):771-777. DOI:10.1080/13543784.2020.1773790
[2] Neesse A, et, al. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30. DOI:10.1073/pnas.1300415110 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|